What the Research Says
Shatavari has been extensively studied in Ayurvedic pharmacological research, though large-scale Western-style RCTs are limited. Alok et al. (2013) published a comprehensive review of its pharmacological properties, documenting estrogenic, galactagogue, anti-ulcer, and immunomodulatory effects. The lactation evidence, while promising, comes from small clinical studies. Gautam et al. (2009) provided strong preclinical evidence for immunomodulatory effects. The main limitation is that most evidence comes from traditional use, animal studies, and small human trials — larger RCTs are needed to confirm efficacy for its primary indications.
Recent studies have explored Shatavari's potential benefits in postmenopausal women. Pingali et al. (2025) conducted a randomized, double-blind, placebo-controlled study and found that ashwagandha and shatavari extracts significantly reduced menopause symptoms, vascular dysfunction, and bone resorption in a dose-dependent manner. O'Leary et al. (2024) reported that six weeks of Shatavari supplementation altered pathways related to muscle adaptation and metabolism in postmenopausal women, as shown in a randomized double-blind trial (N=12). Additionally, O'Leary et al. (2021) found that Shatavari supplementation improved handgrip strength and increased muscle contractility markers in postmenopausal women without affecting bone turnover, based on a randomized double-blind trial (n=20).
Greed et al. (2024) explored the effects of Shatavari supplementation during resistance training in older women. In a randomized, double-blind trial with 17 young and 22 older women, they found that Shatavari supplementation increased training load and improved neuromuscular function in older women.
Overall, while there is promising evidence from recent studies on Shatavari's potential benefits for postmenopausal women and muscle function, larger-scale RCTs are needed to confirm these findings.